NEW YORK (GenomeWeb News) – Goldman Sachs has placed a Buy rating on Hologic with a six-month price target on its stock of $24, as the Gen-Probe acquisition, completed a week ago, is expected to accelerate top line growth.

Analyst Isaac Ro removed his previous Not Rated designation on the Bedford, Mass.-based company and increased revenue estimates for fiscal-year 2012 to $2.00 billion from an earlier estimate of $1.91 billion, but he lowered the EPS estimate to $1.36 from $1.38.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.